Presenters
Professor, University of Tubingen, Germany
Stephan Jacob, MD
Course Details
The aim of this webinar to provide updates on treatment guidelines for patients with T2D with uncontrolled HbA1c, as well as to highlight the importance of early intensification of therapy to prevent the clinical inertia of type 2 diabetes supported by the clinical trials of linagliptin, empagliflozin and the combination empagliflozin + linagliptin.
CPD Points: 0.75 Point
PRC Program No: PROG-2022-25318
The Future of T2D: A Holistic Approach in T2D Management with SGLT2i + DPP4i FDC Course Outline
- Latest guidelines in type 2 diabetes mellitus management and the importance of early intensive therapy
- Evidences to support early intensive therapy with the combination empagliflozin and linagliptin
- To discuss the clinical trial data on the cardio-renal-metabolic benefits of each individual components, Empagliflozin and Linagliptin, with overview discussion on on-going clinical trials exploring potential extended benefits of these
- Course Evaluation